Organisation › Details

Palau Pharma S.A.
Link has been incorrect on 2015-03-31

Palau Pharma is a privately-owned biopharmaceutical company committed to developing innovative medicines that target the unmet needs of patients suffering from inflammatory and autoimmune diseases, such as asthma, rheumatoid arthritis, atopic dermatitis, psoriasis, ulcerative colitis, and others. Palau began its operations in November 2006 and its pipeline includes an extensive portfolio of projects, most of them in clinical development. Additionally, Palau has forged important partnerships with internationally renowned companies. Its current shareholders are Grupo Uriach, Caja Duero, Andosins Capital, CatalunyaCaixa and Najeti Capital. *


Period Start 2006-11-01 start
Period End 2014-12-16 non-existent
  Group Uriach (Group)
Products Industry drug delivery technology (drug formulation technology)
  Industry 2 albaconazole
Persons Person Faus, Ignacio (Mologen 201808–201903 CEO former CEO + Co-Founder of Palau Pharma LEFT EARLY 3/19)
  Person 2 Uriach, Enrique (Palau Pharma 201308 Board Chairman)
Region Region Barcelona
  Country Spain (España)
  Street 51-57 Avda. Camí Reial
  City 08184 Barcelona
  Tel +34-93-864-96-92
    Address record changed: 2018-07-24
Basic data Employees n. a.
    * Document for �About Section�: Actavis, Inc.. (8/6/13). "Press Release: Actavis Acquires Worldwide Rights for Palau Pharma’s Albaconazole Antifungal Agent". Parsippany, NJ & Barcelona.
Record changed: 2018-08-01


Picture [LSUK] – The Business Web Portal 650x99px

More documents for Uriach (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top